METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD)
Clinical trials for METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD) explained in plain language.
Never miss a new study
Get alerted when new METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD) trials appear
Sign up with your email to follow new studies for METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Common vitamin tested as potential treatment for widespread liver condition
Disease control Recruiting nowThis study is testing whether a common vitamin, niacin (vitamin B3), can help reduce fat buildup in the liver of people with fatty liver disease. Researchers will compare niacin against a placebo in 36 participants aged 50-80 to see if it helps the body store fat in healthier pla…
Matched conditions: METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD)
Phase: NA • Sponsor: Université de Sherbrooke • Aim: Disease control
Last updated Apr 03, 2026 14:41 UTC
-
First-in-Human trial targets genetic root of fatty liver disease
Disease control Recruiting nowThis is a very early-stage study testing an experimental drug called ALN-PNP in healthy adults and people with a common fatty liver disease (MASLD). The main goal is to check the drug's safety, how the body processes it, and see if it can reduce liver fat. Researchers will also s…
Matched conditions: METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD)
Phase: PHASE1 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Mar 30, 2026 14:30 UTC
-
First human test for promising fatty liver drug begins
Disease control Recruiting nowThis early-stage study is testing whether a new drug called miricorilant can reduce fat buildup in the liver of people with MASH, a serious form of fatty liver disease. Eight participants will take the drug daily for six weeks while researchers measure changes in liver fat produc…
Matched conditions: METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD)
Phase: PHASE1 • Sponsor: Corcept Therapeutics • Aim: Disease control
Last updated Mar 20, 2026 14:48 UTC